AIM: T0 investigate whether the use of statins is associated with colorectal cancer risk. METHODS: We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National Health Insurance Research Database. Cases consisted ofall patients who were aged 50 years and older and had a first-time diagnosis ofcolorectal cancer between the period 2005 and 2008. The controls were matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multiple logistic regression. RESULTS: We examined 1156 colorectal cancer cases and 4624 controls. The unadjusted ORs for any statin prescription was 1.10 (95% CI = 0.94-1.30) and the adjusted OR was 1.09 (95% CI =0.91-1.30). When statin use was categorized by cumulative dose, the adjusted ORs were 0.99 (95% CI 77w=0.78-1.27) for the group with cumulative statin use below105 defined daily doses (DDDs); 1.07(95% CI7w=0.78-1.49) for the group with cumulative statin use between 106 and 298.66 DDDs; and 1.30 (95% CI0.96-1.75) for the group with cumulative statin use of298.66 DDDs or more compared with nonusers. CONCLUSION: This study does not provide support for a protective effect ofstatins against colorectal cancer.
Date:
2011-12-21
Relation:
World Journal of Gastroenterology. 2011 Dec 21;17(47):5197-5202.
